Nutritional Status of Patients with Chronic Myeloid Leukemia Treated with Imatinib Mesylate

Background : Imatinib mesylate (IM) is the treatment of choice in patients with chronic myeloid leukemia (CML). Among its nonhematological adverse events, water retention is the most common, together with weight gain. However, no thorough description of the body composition in these patients has bee...

Full description

Saved in:
Bibliographic Details
Published in:Nutrition and cancer 2022-08, Vol.74 (9), p.3211-3216
Main Authors: Castillo-Martínez, María José, Tuna-Aguilar, Elena Juventina, Milke-García, María del Pilar, Camacho Zamora, Anaís, Villegas Cervantes, Viviana, Castillo-Martínez, Lilia
Format: Article
Language:English
Subjects:
Bioelectricity
BMI
Body composition
Body mass
Body mass index
Body size
Body weight
Body weight gain
cancer risk
Chronic myeloid leukemia
Depletion
Hematocrit
Hemoglobin
Imatinib
imatinib mesylate
Impedance
Inhibitor drugs
Leukemia
Muscles
muscular depletion
Myeloid leukemia
Nutritional status
obesity
Overweight
Patients
Targeted cancer therapy
Vector analysis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background : Imatinib mesylate (IM) is the treatment of choice in patients with chronic myeloid leukemia (CML). Among its nonhematological adverse events, water retention is the most common, together with weight gain. However, no thorough description of the body composition in these patients has been informed. Therefore, our purpose was to evaluate the nutritional status, body composition and handgrip-strength in patients with CML treated with IM. Methods : We conducted a cross-sectional study in 78 patients (n = 48 men, 30 women) with chronic myeloid leukemia in the chronic (82%) or accelerated (18%) phases. We assessed body mass index (BMI), body composition by bioelectrical impedance, performed vector analysis through Bioelectrical Impedance Vector Analysis, and handgrip-strength measurement in patients with at least 3 months of IM treatment. Hematocrit and hemoglobin values were collected from the medical charts. Results : BMI was within the normal range in 28.2%, indicated overweight in 39.7% and obesity in 30.8%. According to BIVA, 25.6% of the patients were muscle-depleted and were older (p = 0.006) and received lower doses of IM (p 
ISSN:0163-5581
1532-7914
DOI:10.1080/01635581.2022.2069275